Achievement

Ozaki S, Handa H, Saitoh T, Murakami H, Itagaki M, Asaoku H, Suzuki K, Isoda A, Matsumoto M, Sawamura M, Sunami K, Takezako N, Hagiwara S, Kuroda Y, Chou T, Nagura E, Shimizu K. Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma. Ann Hematol. 2019 May 2. doi: 10.1007/s00277-019-03702-1. [Epub ahead of print]
View Article

Kamiya Y, Chou T, Murakami H, Handa H, Ozaki S, Shimazaki C, Fuchida SI, Okada J, Itoh J, Sugiyama S, Shimizu K. Patients assigned to VGPR, PR, and SD in the IMWG response category are composed of heterogeneous population when assessed by the Heavy/Light chain assay. Hematol Oncol. 2019 Apr 2. doi: 10.1002/hon.2611. [Epub ahead of print]

Murakami H, Kasamatsu T, Murakami J, Kiguchi T, Kanematsu T, Ogawa D, Takamatsu H, Handa H, Ozaki S, Miki H, Takahashi T, Takeo T, Yamauchi T, Morishita T, Kosugi H, Shimizu K. Thalidomide maintenance therapy in Japanese myeloma patients: a multicenter, phase II clinical trial (COMET study). Int J Hematol. 2019;109(4):409-417.

Kawamura K, Tsukada N, Kanda Y, Ikeda T, Yoshida A, Ueda Y, Ishida T, Suzuki K, Murakami H. The Role of Allogeneic Transplantation for Multiple Myeloma in the Era of Novel Agents: A Study from the Japanese Society of Myeloma. Biol Blood Marrow Transplant. 2018; 24(7): 1392-1398.

Kasamatsu T, Ozaki S, Saitoh T, Konishi J, Sunami K, Itagaki M, Asaoku H, Cho T, Handa H, Hagiwara S, Wakayama T, Negoro A, Takezako N, Harada N, Kuroda Y, Nakaseko C, Miyake T, Inoue N, Hata H, Shimazaki C, Ohno T, Kuroda J, Murayama T, Kobayashi T, Abe M, Ishida T, Nagura E, Shimizu K. Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma. Hematol Oncol. 2018;36(5):792-800.

Iriuchishima H, Ozaki S, Konishi J, Matsumoto M, Murayama K, Nakamura F, Yamamoto G, Handa H, Saitoh T, Nagura E, Shimizu K, Nojima Y, Murakami H. Primary Plasma Cell Leukemia in the Era of Novel Agents: A Multicenter Study of the Japanese Society of Myeloma. Acta Haematol. 2016; 135(2): 113-21.

Ozaki S, Hata H, Abe M, Saitoh T, Hanamura I, Yano H, Sunami K, Kosugi H, Sawamura M, Nakazato T, Masunari T, Mori M, Takagi T, Murakami H, Shimizu K. Reduced frequency treatment with bortezomib plus dexamethasone for elderly patients with relapsed and/or refractory multiple myeloma: a phase 2 study of the Japanese Myeloma Study Group (JMSG-0902).
Ann Hematol 95(6); 921-9: 2016
View Article

Ozaki S, Handa H, Saitoh T, Murakami H, Itagaki M, Asaoku H, Suzuki K, Isoda A, Matsumoto M, Sawamura M, Konishi J, Sunami K, Takezako N, Hagiwara S, Kuroda Y, Chou T, Nagura E, and Shimizu K. Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Blood Cancer J 2015 (5): e349.
View Article

Ozaki S, Harada T, Saitoh T, Shimazaki C, Itagaki M, Asaoku H, Kuroda Y, Chou T, Yoshiki Y, Suzuki K, Murakami H, Hayashi K, Mina R, Palumbo A, Shimizu K, on behalf of the Japanese Society of Myeloma and the European Myeloma Network. Survival of Multiple Myeloma Patients Aged 65-70 Years in the Era of Novel Agents and Autologous Stem Cell Transplantation. Acta Haematol 2014; 132: 211-219 (DOI:10.1159/000357394)
View Article

Guidelines for Diagnosis and Treatment of Multiple Myeloma III. Edited by Japanese Society of Myeloma, Tokyo, Bunko-do, 2012.

Shimazaki C, Murakami H, Sawamura M, Matsuda M, Kinoshita T, Hata H, Sugiura I, Tsushita K, Nagura E, Kosugi H, Itoh J, Shimizu K. Clinical usefulness of serum free light chain measurement in monoclonal gammopathy. Rinsho Ketsueki. 2010; 51(4): 245-252. Japanese
View Article

Guidelines for Diagnosis and Treatment of Multiple Myeloma II. Edited by Japanese Society of Myeloma, Tokyo, Bunko-do, 2008.

Murakami H, Handa H, Abe M, Iida S, Ishii A, Ishikawa T, Ishida T, Oota M, Ozaki S, Kosaka M, Sakai A, Sawamura M, Shimazaki C, Shimizu K, Takagi T, Hata H, Fukuhara T, Fujii H, Miyata A, Wakayama T, Takatsuki K. Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma. Eur J Haematol. 2007; 79(3): 234-239.
View Article

Shimazaki C, Fujii H, Yoshida T, Chou T, Nishimura M, Asaoku H, Miyawaki S, Ishii A, Ishida T, Taniwaki M, Iida S, Takagi T, Takatsuki K. Reduced-intensity conditioning allogeneic stem cell transplantation for multiple myeloma: Results from the Japan Myeloma Study Group. Int J Hematol 2005; 81: 342-348.
View Article

Murakami H, Fujii H, Inaba T, Shimazaki C, Okamoto S, Miwa A, Sawamura M, Abe M, Chou T, Asaoku H, Kitahara Y, Hayashi K, Kosaka M, Togawa A, Takatsuki K. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in high risk multiple myeloma. Eur J Haematol 2004; 73: 169-173.
View Article

Guidelines for Diagnosis and Treatment of Multiple Myeloma I. Edited by Japanese Society of Myeloma, Tokyo, Bunko-do, 2004.

Murakami H, Handa H, Imai K, Kanakura Y, Kosaka M, Sawamura M, Shimazaki C, Suzuki K, Ishii A, Takagi T, Taniwaki M, Togawa A, Hata H, Wakayama T, Takatsuki K; Japan Myeloma Study Group.Thalidomide treatment of patients with refractory myeloma in the institutes participating in the Japan Myeloma Study Group]. Rinsho Ketsueki 2004;45(6):468-472. Japanese.
View Article

Shimizu K, Nagura E, Takatsuki K. Management of patients with multiple myeloma in Japan: Data of 1,383 patients from 16 hospitals and 1 treatment group. Leukemia & Lymphoma 2004; 45: 2465-2469.
View Article

Chou, T., Kosaka, M, Takagi, T., Togawa, A., Hino, N., Fujii, H., Sezaki, T.: Dose finding study of filgrastim (rhG-CSF) for peripheral blood stem cell harvesting in multiple myeloma patients. The 7th International Myeloma Workshop Abstract Book, P104, 1999

Tsuchiya J, Murakami H, Kanoh T, Kosaka M, Sezaki T, Mikuni C, Kawato M, Takagi T, Togawa A, Isobe T, Suzuki K, Imamura Y and Takatsuki K: Ten-year survival and prognostic factors in multiple myeloma. Japan Myeloma Study Group. Brit J Haematol 1994; 87: 832-834.
View Article

Imamura Y, Takagi T, Yawata Y, Nishinarita S, Kosaka M, Mikuni C, Takatsuki K, Sezaki T, Mori M, Tsuchiya J, Sato N, Isobe T, for the Japan Myeloma Study Group: Combination chemotherapy with MCNU, vindesine, melphalan, and prednisolone (MCNU-VMP therapy) in induction therapy for multiple myeloma. Intern J Hematol 1994; 59: 113-123.
View Article